Deciphering the vedolizumab dosing conundrum in IBD: when less is more.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

1. Amelioration of Acute Oxazolone-Induced Colitis via Oral Administration of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease.Biomedicines · 2026
   Article
2. [Application of advanced treatment in chronic inflammatory bowel diseases].Innere Medizin (Heidelberg, Germany) · 2025
   Review
3. Considerations in Paediatric and Adolescent Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2024
   Review
4. Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.Alimentary pharmacology & therapeutics · 2023
   Article

Corrections and comments

• Comment on
  Residual homing of α4β7-expressing β12022

Authors and funding

2 authors at 2 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as